Xencor (NASDAQ:XNCR) Trading 6.2% Higher - Should You Buy?

Key Points

• Xencor shares rose **6.2%** to **$10.98**, but trading volume decreased significantly to approximately **143,801 shares**, an **82%** decline from average daily volume.
• Analysts have set mixed ratings, with price targets ranging from **$6.00** to **$33.00**; the consensus average target is **$22.25** indicating a **"Moderate Buy."**
• In its latest earnings report, Xencor reported a loss of **($0.41)** per share, surpassing estimates, with revenue of **$43.61 million**, an **82.4%** increase from the same quarter last year.

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) rose 6.2% during trading on Friday . The stock traded as high as $10.92 and last traded at $10.98. Approximately 143,801 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 802,887 shares. The stock had previously closed at $10.33.

Analysts Set New Price Targets

XNCR has been the topic of several research reports. Wells Fargo & Company lowered their price target on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Barclays began coverage on shares of Xencor in a research report on Wednesday, September 17th. They issued an "underweight" rating and a $6.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and set a $26.00 price target on shares of Xencor in a report on Tuesday, September 2nd. Bank of America lowered shares of Xencor from a "buy" rating to a "neutral" rating and lowered their price target for the company from $23.00 to $12.00 in a report on Wednesday, September 3rd. Finally, Royal Bank Of Canada decreased their price objective on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, August 21st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Xencor presently has an average rating of "Moderate Buy" and an average target price of $22.25.

Xencor Trading Up 10.8%

The business's fifty day moving average is $8.50 and its 200 day moving average is $9.12. The firm has a market capitalization of $816.26 million, a P/E ratio of -4.77 and a beta of 0.82.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.37. The business had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The firm's quarterly revenue was up 82.4% compared to the same quarter last year. During the same period last year, the firm posted ($1.07) earnings per share. As a group, sell-side analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of Xencor

Several large investors have recently added to or reduced their stakes in XNCR. Public Employees Retirement System of Ohio bought a new stake in Xencor in the fourth quarter worth approximately $1,227,000. Mackenzie Financial Corp bought a new stake in shares of Xencor during the 4th quarter worth $101,000. California State Teachers Retirement System boosted its holdings in shares of Xencor by 12.1% during the 4th quarter. California State Teachers Retirement System now owns 59,130 shares of the biopharmaceutical company's stock worth $1,359,000 after buying an additional 6,376 shares during the period. Wellington Management Group LLP bought a new stake in shares of Xencor during the 4th quarter worth $632,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Xencor by 348.5% during the 1st quarter. GAMMA Investing LLC now owns 9,629 shares of the biopharmaceutical company's stock worth $102,000 after buying an additional 7,482 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.